FDA cautions against using generic versions of Ozempic and Wegovy.

The FDA has issued a warning about the safety of off-brand versions of the weight-loss drugs Ozempic and Wegovy, which contain the active ingredient semaglutide. The agency has received reports of adverse events after people took semaglutide from compounding pharmacies, which are not reviewed for safety, effectiveness, or quality. Some compounding pharmacies claiming to sell semaglutide might instead be selling other formulations of the chemical, which haven't been shown to be safe or effective. Patients should not use a compounded drug if an approved drug is available to treat them, the FDA said.